Absence of compensatory platelet activation in patients with severe haemophilia, but evidence for a platelet collagen-activation defect

Platelets

Volumn 13, Issue 8, 2002, Pages 451-458

  Grünewald, Martin ^a   Siegemund, Annelie ^b   Grünewald, Anja ^a   Konegen, Anke ^a   Koksch, Mario ^b   Griesshammer, Martin ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; FIBRINOGEN RECEPTOR; RISTOCETIN; THROMBIN; THROMBOSPONDIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; COLLAGEN;

ARTICLE; BLOOD CLOTTING; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FLOW CYTOMETRY; HEMOPHILIA; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHEAR STRESS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; ADOLESCENT; ADULT; AGED; BLOOD; CHILD; COMPARATIVE STUDY; DRUG EFFECT; HEMOPHILIA A; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; REFERENCE VALUE; THROMBOCYTE; THROMBOCYTE ADHESIVENESS;

ADENOSINE DIPHOSPHATE; ADOLESCENT; ADULT; AGED; BLOOD COAGULATION; BLOOD PLATELETS; CHILD; COLLAGEN; EPINEPHRINE; FACTOR IX; FACTOR VIII; FLOW CYTOMETRY; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET ADHESIVENESS; REFERENCE VALUES; RISTOCETIN; THROMBIN;

EID: 18744388828     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/0953710021000059422     Document Type: Article

References (47)

1. Gaffney PJ, Edgell TA, Whitton CM. The haemostatic balance - Astrup revisited. Haemostasis 1999; 29: 58-71.
2. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477: 349-60.
3. Dahlback B. Blood coagulation. Lancet 2000; 355: 1627-32.
4. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. New Engl J Med 1999; 340: 1555-64.
5. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-15.
6. Tschoepe D, Spangenberg P, Esser J, Schwippert B, Kehrel B, Roesen P, et al. Flow-cytometric detection of surface membrane alterations and concomitant changes in the cytoskeletal actin status of activated platelets. Cytometry 1990; 11: 652-6.
7. Escolar G, White JG. Changes in glycoprotein expression after platelet activation: Differences between in vitro and in vivo studies. Thromb Haemost 2000; 83: 371-86.
8. Schmitz G, Rothe G, Ruf A, Barlage S, Tschope D, Clemetson KJ, et al. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-96.
9. Mammen EF. Ten years' experience with the 'sticky platelet syndrome'. Clin Appl Thromb Hemost 1995; 1: 66-72.
10. Janes SL, Wilson DJ, Chronos N, Goodall AH. Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen on normal subjects and patients with activated platelets. Thromb Haemost 1993; 70: 659-66.
11. Griesshammer M, Beneke H, Nussbaumer B, Grünewald M, Bangerter M, Bergmann L. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb Res 1999; 96: 191-6.
12. Koksch M, Zeiger F, Wittig K, Siegemund A, Reininger CB, Pfeiffer D, et al. Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease. Eur J Vasc Endovasc Surg 2001; 21: 147-54.
13. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991; 17: 433-8.
14. Kannan K, Divers SG, Lurie AA, Chervenak R, Fukuda M, Holcombe RF. Cell surface expression of lysosome-associated membrane protein-2 (lamp2) and CD63 as markers of in vivo platelet activation in malignancy. Eur J Haematol 1995; 55: 145-51.
15. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. JACC 1998; 31: 352-58.
16. Zeller JA, Tschoepe D, Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 1999; 81: 373-7.
17. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115: 451-9.
18. Wang ZY, Shi JM, Han Y, Wang YC, Ruan CG. Comparative study of platelet activation markers in diabetes mellitus patients complicated by cerebrovascular disease. Blood Coagul Fibrinolysis 2001; 12: 531-7.
19. Yamazaki M, Uchiyama S, Iwata M. Measurement of platelet fibrinogen binding and p-selectin expression by flow cytometry in patients with cerebral infarction. Thromb Res 2001; 104: 197-205.
20. Olinde JG, Zibari GB, Brown MF, Howell JG, Akgur FM, Granger DN, et al. Persantine attenuates hemorrhagic shock-induced P-selectin expression. Am Surg 2000; 66: 1093-7; discussion 97-8.
21. Akgur FM, Brown MF, Zibari GB, McDonald JC, Epstein CJ, Ross CR, et al. Role of superoxide in hemorrhagic shock-induced P-selectin expression. Am J Physiol Heart Circ Physiol 2000; 279: H791-7.
22. Nurden AT. Inherited abnormalities of platelets. Thromb Haemost 1999; 82: 468-80.
23. Subramaniam M, Frenette PS, Saffaripour S, Johnson RC, Hynes RO, Wagner DD. Defects in hemostasis in P-selectin-deficient mice. Blood 1996; 87: 1238-42.
24. Mazurov AV, Vinogradov DV, Khaspekova SG, Krushinsky AV, Gerdeva LV, Vasiliev SA. Deficiency of P-selectin in a patient with grey platelet syndrome. Eur J Haematol 1996; 57: 38-41.
25. Lages B, Sussman, II, Levine SP, Coletti D, Weiss HJ. Platelet alpha granule deficiency associated with decreased P-selectin and selective impairment of thrombin-induced activation in a new patient with gray platelet syndrome (alpha-storage pool deficiency). J Lab Clin Med 1997; 129: 364-75.
26. Kehrel B, Balleisen L, Kokott R, Mesters R, Stenzinger W, Clemetson KJ, et al. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood 1988; 71: 1074-8.
27. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Factor VIII and Factor IX Subcommittee. Thromb Haemost 2001; 85: 560.
28. Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000; 40: 1509-15.
29. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 2000; 40: 124-32.
30. Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
31. Hartert H. Blutgerinnungsstudien mit der Thrombelastographie. Kiln Wschr 1948; 26: 577-82.
32. Mallett SV, Cox DJA. Thrombelastography. Br J Anesthesia 1992; 69: 307-13.
33. Kratzer MAA, Born GVR. Simulation of primary hemostasis in vitro. Haemostasis 1985; 15: 357-62.
34. Kratzer MAA, Bellucci S, Caen JP. Detection of abnormal platelet function with an in vitro model of primary hemostasis. Haemostasis 1985; 15: 363-70.
35. Hellem AJ. Platelet adhesiveness in von Willebrand's disease. A study with a new modification of the glass bead filter method. Scand J Haematol 1970; 7: 374-82.
36. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-29.
37. Ginsberg MH, Frelinger AL, Lam SC-T, Forsyth J, McMillan R, Plow EF, et al. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood 1990; 76: 2017-23.
38. Santoro SA. Platelet surface collagen receptor polymorphisms: Variable receptor expression and thrombotic/hemorrhagic risk. Blood 1999; 93: 3575-7.
39. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001; 86: 189-97.
40. Watson SP, Asazuma N, Atkinson B, Berlanga O, Best D, Bobe R, et al. The role of ITAM- and ITIM-coupled receptors in platelet activation by collagen. Thromb Haemost 2001; 86: 276-88.
41. Di Paola J, Federici AB, Mannucci PM, Canciani MT, Kritzik M, Kunicki TJ, et al. Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood 1999; 93: 3578-82.
42. Hoffman M, Monroe DM, 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
43. Galvez A, Gomez-Ortiz G, Diaz-Ricart M, Escolar G, Gonzalez-Sarmiento R, Zurbano MJ, et al. Desmopressin (DDAVP) enhances platelet adhesion to the extracellular matrix of cultured human endothelial cells through increased expression of tissue factor. Thromb Haemost 1997; 77: 975-80.
44. Sloand EM, Alyono D, Klein HG, Chang P, Yu M, Lightfoot FG, et al. 1-Deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass. Am J Hematol 1994; 46: 199-207.
45. Wun T, Paglieroni TG, Lachant NA. Desmopressin stimulates the expression of P-selectin on human platelets in vitro. J Lab Clin Med 1995; 126: 401-9.
46. Shapiro AD. Platelet function disorders. Haemophilia 2000; 6: 120-7.
47. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first twenty years. Haemophilia 2000; 6: 60-7.